InORS - International Observational Registry on Schizophrenia With Injectable Risperidone and Oral Antipsychotics

• Status: Completed
• Trial end date: 2012-03-01
• Target enrollment: 0
• Participant gender: All

Summary

International Observational Registry on Schizophrenia

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Janssen-Cilag International NV
• Treatments: Antipsychotic Agents; Risperidone

Criteria

Inclusion Criteria:

• Patients must satisfy the following criteria to be eligible for documentation in this non-interventional study: Diagnosis of schizophrenia as well as 6 months of retrospective clinical records

• Newly initiated on or switched to RLAI or an oral antipsychotic treatment (either atypical or conventional), not longer than 2 weeks ago

• Signed informed consent (either signed by the patient or his/her legal representative) is available at the beginning of documentation

• any schizophrenic patient (including those for whom a legal representative must sign consent) can be involved in the study

Exclusion Criteria:

• Established treatment refractory schizophrenia, defined as treatment failures with adequate trials (adequate as judged by the treating physician) of more than 2 second generation (atypical) antipsychotics and/or clozapine

• History of neuroleptic malignant syndrome